A Mayo Clinic Division of Cardiovascular Medicine research team reports that obese adults with prediabetes taking GLP-1 peptide drugs were 31% less likely to progress to type 2 diabetes than metformin users, according to a retrospective review of electronic medical records covering 256,492 patients across 104 medical institutions from 2010 to 2023. The findings, which also show a 41% lower all-cause mortality risk in the GLP-1 group, are scheduled for presentation at the 2026 American Heart Association Scientific Sessions in Chicago (November 6–9) and have not yet been published in a peer-reviewed journal.
The result matters to the peptide therapy and research peptide industry because prediabetes represents one of the largest potential patient pools for GLP-1 prescribing, and because the comparison is against metformin — an inexpensive, decades-old generic that clinicians have long treated as the default first-line option. Any shift in prescribing logic toward GLP-1 peptides in prediabetes would ripple through clinic protocols, telehealth intake criteria, compounding and API demand, and the supply chain that serves them. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What the Mayo Clinic study actually found
The study compared two treatment cohorts drawn from electronic medical records: patients prescribed metformin and patients prescribed one of four GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide or dulaglutide. The cohort averaged 52 years of age, and patients were followed for an average of about three years within the 2010–2023 data window.
According to the study authors, as reported by 헬스조선, the GLP-1 group was 1.5 times more likely than the metformin group to return blood glucose levels to the normal range. Risk of progressing to diabetes was 31% lower, and risk of death from all causes was 41% lower. Cardiovascular outcomes also differed: compared with the metformin group, the GLP-1 group had 15% fewer myocardial infarctions, 20% fewer strokes, 25% fewer heart failure cases and 8% fewer atrial fibrillation cases.
Two caveats belong next to those numbers. First, this is an observational record review; the source reporting does not describe randomization or the statistical adjustment methods used, so the figures represent observed associations rather than demonstrated causal effects. Second, the results were scheduled for conference presentation, which typically precedes peer review. Readers should treat the percentages as reported findings awaiting full methodological disclosure.
Key numbers at a glance
| Measure | GLP-1 group vs. metformin group |
|---|---|
| Patients reviewed | 256,492 obese adults with prediabetes (average age 52) |
| Data sources and window | 104 medical institutions, 2010–2023 |
| Average follow-up | About three years |
| Return to normal blood glucose | 1.5 times more likely |
| Progression to diabetes | 31% lower risk |
| All-cause mortality | 41% lower risk |
| Myocardial infarction | 15% fewer cases |
| Stroke | 20% fewer cases |
| Heart failure | 25% fewer cases |
| Atrial fibrillation | 8% fewer cases |
Why it matters for peptide therapy clinics and prescribing
The clinical significance of prediabetes is that it sits upstream of both diabetes and cardiovascular disease. The researchers stated that prediabetes is a stage that can be reversed to normal through lifestyle improvements and early treatment, and that prescribing GLP-1 drugs during the prediabetes stage could be considered based on an individual’s overall health status and underlying conditions. That is a conditional statement, not a guideline change, and it leaves room for clinician judgment.
For peptide therapy clinics and telehealth operators, the practical question is triage rather than blanket adoption. A 52-year-old patient with prediabetes, elevated cardiovascular risk and obesity is a different prescribing conversation from a lean patient with mildly elevated fasting glucose. Clinics that build intake workflows around cardiovascular risk stratification — rather than around weight loss alone — will be better positioned to apply findings like these responsibly. Prescription and medical supervision remain the governing requirement; GLP-1 peptides are approved medicines only for their labeled indications, and use in prediabetes outside those labels is a clinical decision that depends on the specific product, jurisdiction and patient.
The researchers were explicit that this does not mean GLP-1 drugs should uniformly replace metformin, as metformin is inexpensive and has been shown to be safe over the long term. Cost, tolerability, gastrointestinal side effects, lean mass loss during rapid weight reduction and long-term adherence all remain part of the calculus. Industry observers note that the comparison in this study is between two active treatments, not between treatment and placebo, which makes the findings more clinically interesting but also more sensitive to differences in who receives which drug in routine practice.
Research and market context: what the evidence does and does not establish
The GLP-1 class has moved in roughly a decade from a diabetes-only niche to the center of metabolic medicine. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors; their approved products, indications, dosing, contraindications and labeling differ, and medical decisions should be based on the relevant product labeling and professional evaluation. Liraglutide and dulaglutide, the other two agents in this cohort, have their own distinct profiles.
The researchers suggested that the weight-loss and blood glucose improvement effects of GLP-1 drugs may have contributed to the reduced risks of diabetes progression and cardiovascular disease. That mechanism is plausible but hedged — the source reporting does not describe a mediation analysis, and other pathways, including anti-inflammatory effects and residual confounding, cannot be excluded from the available information. The distinction matters for anyone building a clinical protocol on top of this data: an association consistent with a mechanism is not the same as a demonstrated mechanism.
For research peptide suppliers and buyers, the study reinforces a familiar quality-control point. A peptide’s identity and purity are not the same as clinical evidence. A research peptide is a peptide supplied for a defined scientific or laboratory research purpose, and a research-use designation does not establish suitability, sterility, safety or authorization for human administration. Buyers evaluating GLP-1-related materials should confirm sequence or chemical identity, salt form, molecular weight, stated purity method, batch number and supporting analytical documentation before treating any material as comparable to an approved product.
Supply chain and manufacturing read-across
If GLP-1 prescribing in prediabetes expands, the pressure point is unlikely to be scientific consensus — it will be manufacturing capacity and finished-product supply. Peptide APIs are produced through chemical synthesis routes such as solid-phase peptide synthesis, and a peptide API is only the active ingredient; a finished drug product combines that ingredient with formulation, container closure, manufacturing controls, labeling and release requirements. API quality alone does not establish finished-product quality or regulatory approval.
On the packaging side, GLP-1 products reach patients through vials, dual-chamber cartridges and injection pens, each with its own fill-finish, container-closure integrity and stability considerations. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. For teams tracking how demand signals translate into orders, peptidescm maintains supply chain and industry resources that follow these categories.
Analysts should be careful not to over-read a single conference abstract as a demand forecast. The available evidence does not yet establish that prediabetes prescribing will scale, that payers will reimburse it, or that supply will tighten as a result. What the study does provide is a credible clinical rationale that clinic operators, telehealth platforms and suppliers may need to respond to if guideline bodies and payers follow.
What comes next
The immediate milestone is the presentation at the 2026 American Heart Association Scientific Sessions in Chicago, where the full methodology — cohort definitions, adjustment variables, follow-up handling and sensitivity analyses — should become visible. Peer-reviewed publication would be the next gate. Until then, the appropriate posture for clinics is to note the signal, keep metformin in the conversation, and avoid rewriting protocols on the strength of a conference abstract.
For the peptide supply chain, the watch items are narrower: whether GLP-1 API and finished-product capacity announcements track the clinical narrative, whether vial, cartridge and pen component supply keeps pace, and whether quality documentation standards tighten as more buyers enter the category. PeptideDDP’s business manager Sarah provided the news lead behind this report, which was edited with publicly available information; the original information originates from PeptideDDP.com.
FAQ
Did the Mayo Clinic study prove that GLP-1 drugs are better than metformin?
No. The study is a retrospective review of electronic medical records and reports lower observed rates of diabetes progression, death and cardiovascular events among GLP-1 users. The source reporting does not describe randomization or adjustment methods, and the findings were scheduled for conference presentation rather than peer-reviewed publication.
How many patients were included and over what period?
The review covered 256,492 obese adults with prediabetes, average age 52, using data from 104 medical institutions between 2010 and 2023, with average follow-up of about three years.
Which GLP-1 drugs were included?
The GLP-1 treatment group included patients who used semaglutide, tirzepatide, liraglutide or dulaglutide.
Should patients with prediabetes ask for a GLP-1 drug instead of metformin?
That is a clinical decision. The researchers stated that GLP-1 drugs should not uniformly replace metformin given its low cost and long-term safety record, and that GLP-1 prescribing in prediabetes could be considered based on an individual’s overall health status and underlying conditions. Patients should discuss options with a licensed clinician.
Are research peptides a substitute for prescribed GLP-1 medicines?
No. Research peptides are supplied for laboratory research purposes and are not authorized for human administration; research-use labeling does not establish sterility, safety or clinical efficacy.
Comments